ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 55

Validation of the Diagnosis of Avascular Necrosis of Bone in Administrative Data

Medha Barbhaiya1, Yan Dong2, Jeffrey A. Sparks1, Elena Losina2, Karen H. Costenbader1 and Jeffrey N. Katz3, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 3Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: avascular necrosis and osteonecrosis, ICD-9

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More

Session Type: Abstract Submissions (ACR)

Background/Purpose: Avascular necrosis (AVN) of bone is a painful, disabling condition. Studies aimed at improving the diagnosis or treatment of AVN require accurate case-finding methods. We examined the sensitivity, specificity, positive predictive value (PPV) and positive likelihood ratio (LR+) of alternative algorithms that use claims data to identify cases of AVN of the upper and lower extremities.

Methods: Using a centralized clinical data registry from a large academic hospital, we identified all adults aged ≥18 years who underwent MRI of an upper and/or lower extremity joint for any indication between January 1, 2010 and June 1, 2011. We examined the performance characteristics (sensitivity, specificity, PPV, and LR+) of four algorithms (A – D) using International Classification of Diseases, 9th edition (ICD-9) codes for AVN (ICD-9, 733.4X) (Table). The algorithms ranged from least stringent (Algorithm A, requiring ≥1 1 ICD-9 code) to most stringent (Algorithm D, requiring ≥ 3 ICD-9 codes at least 30 days apart). Only ICD-9 codes within 6 months of MRI diagnosis were included. We compared cases identified by each algorithm to the gold standard of a clinical MRI reading by a radiologist confirming “avascular necrosis” or “osteonecrosis.” We calculated 95% confidence intervals (CI) using the normal approximation of the binomial distribution. 

Results: A total of 11,878 patients who underwent MRI of the upper and lower extremities during the 1.5 year period were included in this study.  The prevalence of AVN using the gold standard of MRI was 0.7%, with 83 total cases of AVN. Algorithm A had a sensitivity of 81.9% (95% CI 71.9-89.5), with a PPV of 48.6% (95%CI 40.0-57.2) and a LR+ of 134 (95% CI 104-173). The PPV of algorithm D increased to 61.4% (95% CI 47.6-74.0) with a LR+ of 226 (95% CI 139-368), although the sensitivity decreased to 42.2% (95% CI 31.4-53.5) (Table). The specificity of all four algorithms ranged from 99.0 to 99.8%.

Conclusion: In this study, we demonstrated that the PPV for AVN among patients who underwent MRI ranged from 49-61% in different ICD-9 code-based algorithms. Given its high sensitivity, Algorithm A (requiring at least 1 ICD-9 code for AVN) appears best suited for situations in which it would be problematic to miss AVN cases, and confirming cases to exclude false positives with further chart review is feasible.  Algorithm B, requiring ≥2 ICD-9 codes at least 7 days apart, had the highest PPV and might be recommended when further validation is not feasible, although misclassification may occur. These algorithms provide an efficient way to identify AVN cases in administrative data, and the PPVs will be greater in populations with higher disease prevalence such as SLE or orthopedic cohorts. Of note, since all patients in this study underwent MRI, cases of asymptomatic or mild AVN that did not prompt MRI evaluation would not be detected with these methods.

Table. Performance characteristics of ICD-9 code algorithms for the diagnosis of avascular necrosis (AVN) of bone

Algorithms

Sensitivity
(95% CI),%

Specificity
(95% CI), %

PPV
(95% CI),%

LR+
(95% CI)

A: ≥1 ICD-9 code for AVN

81.9 (71.9-89.5)

99.4 (99.2-99.5)

48.6 (40.0-57.2)

134.2 (104.4-172.6)

B: ≥2 ICD-9 codes for AVN at least 7 days apart

56.6 (45.3-67.5)

99.8 (99.7-99.8)

62.7 (50.7-73.6)

238.5 (157.5-361.3)

C: ≥2 ICD-9 codes for AVN at least 30 days apart

42.2 (31.4-53.5)

99.8 (99.7-99.9)

60.3 (46.6-80.0)

216.3 (133.9- 349.4)

D: ≥3 ICD-9 codes for AVN at least 30 days apart

42.2 (31.4-53.5)

99.8 (99.7-99.9)

61.4 (47.6-74.0)

226.1 (138.8-368.2)


Disclosure:

M. Barbhaiya,
None;

Y. Dong,
None;

J. A. Sparks,
None;

E. Losina,
None;

K. H. Costenbader,
None;

J. N. Katz,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-diagnosis-of-avascular-necrosis-of-bone-in-administrative-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology